Nearly 1 in 6 Pediatric GLP-1 Patients Diagnosed With Nutritional Deficiency Within a Year
Nearly one in six children and adolescents who started a GLP-1 receptor agonist were diagnosed with a nutritional deficiency or deficiency-related complication within one year, according to a retrospective analysis of insurance claims published in Childhood Obesity. Vitamin D deficiency was the most common diagnosis. The study also found that nutrition counseling was infrequent and often began months after treatment started. The authors cautioned that the findings do not show counseling causes deficiencies and that a study designed to test causation is needed. The analysis covered 2,031 patients aged 10 to 17 years, drawn from claims data from 2017 to 2022.

- Nearly 1 in 6 pediatric patients who started a GLP-1 receptor agonist had a nutritional deficiency or related complication diagnosed within one year.
- Vitamin D deficiency was the most frequent diagnosis, at 12.4% at one year.
- Only 23.3% of patients had a nutrition therapy or counseling visit within 180 days of starting treatment.
- The mean time to the first nutrition visit was 149 days after treatment began.
- Patients with an early nutrition visit had higher deficiency rates, though the authors said this does not show counseling causes deficiencies.
- Claims-based diagnosis codes may under-report subclinical deficiencies and exclude lab values and dietary intake.
- Two 2025 publications recommend a baseline nutrition assessment before starting GLP-1 therapy.
Nearly one in six pediatric patients who started a glucagon-like peptide-1 receptor agonist (GLP-1 RA) were diagnosed with a nutritional deficiency or deficiency-related complication within one year, according to a retrospective analysis of insurance claims published in Childhood Obesity. The same data show that nutrition counseling was uncommon and often did not begin until months after treatment started.
The research team analyzed Inovalon claims data from 2017 to 2022, covering more than 100 million patients. They identified 2,031 GLP-1 RA users aged 10 to 17 years who met continuous enrollment criteria and had no prior diagnosis of a nutritional deficiency. Patients with type 1 diabetes were excluded. The mean age was 15 years, 61.5% were female, 67.2% had type 2 diabetes, and 62.6% had obesity, based on diagnosis codes. Liraglutide (Victoza, Saxenda) accounted for 78.6% of initiations, followed by dulaglutide (Trulicity) at 10.4% and semaglutide (Ozempic, Wegovy) at 9.1%.
Vitamin D deficiency led the diagnoses
How Common Are Nutritional Deficiencies in Children Taking GLP-1 Drugs?
Diagnoses of any nutritional deficiency or deficiency-related complication reached 10.2% within 180 days and 16.8% within 365 days (95% CI, 15.2%-18.5%). Vitamin D deficiency was the most frequent single diagnosis, at 12.4% (95% CI, 11.0%-13.9%) at one year. Nutritional anemia was diagnosed in 1.55% of patients, iron-deficiency anemia in 1.44%, and muscle loss in 0.8%.
The authors pointed to a prior study of adults with type 2 diabetes in which 12.7% developed a nutritional deficiency or related complication within six months. That figure rose to 22.4% by 12 months.
Justin Ryder, PhD, vice chair of research for the Department of Surgery at Ann & Robert H. Lurie Children's Hospital of Chicago and associate professor of surgery and pediatrics at Northwestern University Feinberg School of Medicine, said the findings matter as use expands. "As appropriate pediatric use of GLP-1s becomes more widespread, we need to understand the risks during periods of rapid growth and pubertal development," he said in a news release.
Nutrition counseling lagged behind treatment
Why Does Nutrition Counseling Matter for Pediatric GLP-1 Patients?
Nutrition therapy and counseling (NT/C) was used infrequently and late. Visits occurred within 30 days for 5.8% of patients, within 90 days for 14.7%, within 180 days for 23.3%, and within 365 days for 38.3%. The mean time to the first visit was 149 days. Before starting therapy, 29.1% of patients had a dietitian visit.
Patients who had an NT/C visit in the first 180 days were more likely to have a deficiency diagnosis. At 365 days, 23.2% of the 474 patients with a visit had a diagnosed deficiency or complication, compared with 14.8% of the 1,557 without one (P <.01). The authors were careful about interpreting that gap. Patients may have been referred after a deficiency was already detected, or visits with a registered dietitian nutritionist or other provider may have prompted testing that uncovered more deficiencies. A study designed to test causation is needed to sort out those explanations, they wrote.
Ryder said the results suggest nutrition support should not wait for a problem to appear. "Nutritional support needs to play a critical role once treatment with a GLP-1 medication is initiated," he said. He added that nutrition care may need to begin alongside treatment rather than after a deficiency has been detected.
The study did not assess pharmacist involvement. Pharmacists, however, can ask about dietary intake during counseling and recommend appropriate laboratory testing or supplements. A 2025 multisociety advisory recommended a baseline nutrition and micronutrient assessment for patients starting GLP-1 therapy. A separate 2025 narrative review in Obesity Pillars recommended nutrition assessment before treatment with an obesity medication begins, preferably by a registered dietitian. Its authors wrote that many patients on GLP-1-based therapies do not receive appropriate nutrition advice.
What Are the Limits of This GLP-1 Deficiency Study?
The study has clear limits. Deficiencies were identified from claims-based diagnosis codes, which may under-report subclinical deficiencies and do not include laboratory values or dietary intake. Some deficiencies may have been present but undiagnosed before therapy began. The data did not include Medicaid enrollees, and the study period largely preceded approval of semaglutide for patients aged 12 to younger than 18 years. Claims data also cannot explain why NT/C use was low. The authors listed provider availability, insurance coverage, and patient preference as possible factors.
FAQ
- How many pediatric GLP-1 patients were diagnosed with a nutritional deficiency within a year?
- Nearly one in six. The analysis found 16.8% were diagnosed with a nutritional deficiency or deficiency-related complication within 365 days.
- What was the most common nutritional deficiency diagnosis?
- Vitamin D deficiency was the most frequent single diagnosis, at 12.4% of patients at one year.
- Was nutrition counseling started early for pediatric GLP-1 patients?
- No. Visits occurred within 30 days for 5.8% of patients, and the mean time to the first visit was 149 days.
Read next
GLP-1 Drugs Do Not Change Injection Needs for Diabetic Macular Edema, Study Finds
GLP-1 receptor agonists did not significantly change how often patients with diabetic macular edema needed anti-VEGF injections, according to a large retrospective cohort study presented at the American Academy of Ophthalmology meeting in New Orleans. Over 24 months of follow-up, treatment frequency showed no sustained or progressive change after patients started a GLP-1 drug, compared with matched patients who did not. Visual acuity and retinal thickness also held steady. Researchers said the results are reassuring amid ongoing uncertainty about the drugs' eye safety, though they cautioned that more research is needed.

GLP-1 Medications Show Promise in Treating Obesity and Improving Fertility
Research on GLP-1 medications has yielded promising results in treating obesity and improving fertility in men with low testosterone. A study found that GLP-1s may improve testosterone levels and sperm quality, while another study showed a 310-fold increase in GLP-1 prescriptions for children with obesity.

GLP-1 Drug Linked to Dangerous Lithium Spike, While MS Study Finds Fewer Relapses
A case report describes a 50-year-old woman with bipolar disorder whose lithium levels rose to toxic range after she started tirzepatide (Zepbound), a GLP-1 weight loss drug. Her symptoms eased after her lithium dose was lowered. Separately, a large U.S. real-world study presented at MSToronto2026 found that multiple sclerosis patients taking GLP-1 receptor agonists had fewer relapses, optic neuritis episodes and demyelinating events than patients who did not take them. Researchers say the findings are early and call for more investigation into both the interaction risk and the potential benefits.

Medicare's GLP-1 Discount Program Leaves Many Patients Behind
A new Medicare pilot program offers discounted GLP-1 medications for weight loss, but millions of patients are excluded due to pre-existing medical conditions, leaving them with unaffordable treatment options.

Low T in Army Men, GLP-1 Blood Pressure Data and Retatrutide Side Effects Make the News
A new round of health research points to a wide range of hormone and metabolic findings. Roughly a quarter of active-duty U.S. Army men had a morning testosterone level under 300 ng/dL, a common cutoff for low testosterone. A CDC report found nearly half of American women ages 40 to 60 reported menopausal symptoms in 2025, and 15.6% of them took prescription medication for those symptoms. Separate studies linked GLP-1 drugs to blood pressure drops and early anti-aging signals. Novo Nordisk reported weight-loss results in women, and Walmart said it will cover over 250 prescription drugs, including some GLP-1 drugs for diabetes, for employees in 2027. An analysis of Reddit posts also cataloged side effects reported by users of the unapproved weight-loss drug retatrutide.